A venture capital firm founded in 2019 and headquartered in the US invests in early-stage life science companies, typically in Series A, with a focus on companies with smaller capital requirements. Average check size is $8M USD but can range from $1M-15M USD. The firm typically leads rounds but can also participate in syndicates. Though the firm has not invested in a startup abroad, they are open to global opportunities.
The firm is interested in all sectors of life science, but 80% of their interest is drugs. The remaining 20% is focused on other life science verticals such as devices and diagnostics. Areas of interest include orphaned assets, promising data that could potentially be out-licensed but was overlooked, or nutraceutical products that are being developed into drugs. The firm is indication-agnostic, however, gravitates towards and prefers niche areas such as ophthalmology, rare diseases, dermatology, psychiatry, and cardiometabolic diseases. Ideally, the firm would like to fund proof-of-concept data.
The firm requires to take a board seat. The firm does not have strict company or management team requirements.
If you are interested in more information about this investor and other investors tracked by LSN, please email salescore@lifesciencenation.com.
Next Phase Newsletter 
Leave a comment